Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care
L Quartuccio, A Sonaglia, D McGonagle… - Journal of Clinical …, 2020 - Elsevier
Objective Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care
L Quartuccio, A Sonaglia… - JOURNAL OF …, 2020 - irinsubria.uninsubria.it
Objective: Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or" …
a life-threatening pneumonia that often occurs in the setting of increased inflammation or" …
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care.
L Quartuccio, A Sonaglia, D McGonagle, M Fabris… - 2020 - pesquisa.bvsalud.org
ObjectiveApproximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or" …
a life-threatening pneumonia that often occurs in the setting of increased inflammation or" …
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care
L Quartuccio, A Sonaglia, D McGonagle, M Fabris… - medRxiv, 2020 - medrxiv.org
Objective Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …
[HTML][HTML] Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care
L Quartuccio, A Sonaglia, D McGonagle, M Fabris… - 2020 - europepmc.org
Objective Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care
L Quartuccio, A Sonaglia, D McGonagle… - 2020 - expeditiorepositorio.utadeo.edu.co
Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop a life-
threatening pneumonia that often occurs in the setting of increased inflammation or “cytokine …
threatening pneumonia that often occurs in the setting of increased inflammation or “cytokine …
[PDF][PDF] Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care
L Quartuccio, A Sonaglia, D McGonagle… - Journal of Clinical …, 2020 - umfcs.u-bordeaux.fr
Objective: Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care
L Quartuccio, A Sonaglia, D Mcgonagle… - JOURNAL OF …, 2020 - air.uniud.it
Objective: Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care.
L Quartuccio, A Sonaglia, D McGonagle, M Fabris… - 2020 - cabidigitallibrary.org
Objective: Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or" …
a life-threatening pneumonia that often occurs in the setting of increased inflammation or" …
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care
L Quartuccio, A Sonaglia… - Journal of clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Objective Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or" …
a life-threatening pneumonia that often occurs in the setting of increased inflammation or" …